Tris Pharma names Curatolo to lead its ADHD portfolio

Tris Pharma Inc., a Monmouth Junction-based pharmaceutical company, has appointed Thomas Curatolo as chief commercial officer to lead its ADHD portfolio, it announced Wednesday.

Curatolo, who has more than 20 years of experience in commercial branding, spent most of the last two decades working on or leading Attention Deficit Hyperactivity Disorder brands. He spent 10 years with Shire Pharmaceuticals, then another 10 years at Johnson & Johnson.

“Tom’s track record, especially within the ADHD category, coupled with his extensive experience in pharmaceutical sales, sales management and marketing, makes him an ideal leader for our expanded ADHD business,” Ketan Mehta, founder and CEO of Tris. “Along with Barry Herman … Tris’ Chief Medical Officer, who is building a world-class medical affairs team, we are poised to become a leading ADHD company.”

“I am honored to have the opportunity to lead Tris’ commercial organization, and recognize that with our recent acquisition, we are now positioned to establish Tris as a leader in the ADHD category,” Curatolo said. “I look forward to working with my colleagues at Tris to help improve the lives of patients we serve.”

Curatolo earned his MBA in marketing management from St. John’s University and a bachelor’s degree in environmental economics from Rutgers University.